Induction of anticentromere antibody in patients receiving treatment with D-penicillamine.
Anticentromere antibody (ACA) was previously described as a specific marker for CREST, progressive systemic sclerosis (PSS), scleroderma (SCL), Raynaud's phenomenon (RP) and primary biliary cirrhosis (PBC). In this present investigation ACA was observed appearing and disappearing due to D-penicillamine (DPA) treatment in 7 patients without any features of CREST, PSS, SCL, RP or PBC. HLA-DR3 was found in 5/7 of these patients. DPA induced ACA should be added to adverse immunologic drug reactions.
Haberhauer
G
G
2. Medizinische Abteilung, Kaiser-Franz-Josef-Spital, Wien.
D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001323:Autoantibodies / Q000032:analysis*; D001327:Autoimmune Diseases / Q000139:chemically induced*; D002503:Centromere / Q000276:immunology*; D002875:Chromosomes / Q000276:immunology*; D004247:DNA / Q000276:immunology; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000009:adverse effects* / Q000627:therapeutic use
D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D007070:Immunoglobulin A; D007075:Immunoglobulin M; D004247:DNA; D010396:Penicillamine